[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] Erratum. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2020, 70(4): 313. [3] Kloeckner R, Galle PR, Bruix J.Local and Regional Therapies for Hepatocellular Carcinoma[J]. Hepatology, 2021,73(Suppl 1): 137-149. [4] Park JW, Chen M, Colombo M, et al.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166. [5] Xie DY, Ren ZG, Zhou J, et al.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463. [6] Prince D, Liu K, Xu W, et al.Management of patients with intermediate stage hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2020, 12: 1758835920970840. [7] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤防治研究, 2022, 49(3): 251-276. [8] 何坤, 何泳铸, 胡泽民, 等. 肝癌射频消融术后复发危险因素分析及术前预测评分[J]. 中华肝胆外科杂志, 2021, 27(3): 169-174. [9] Feng H, Li B, Li Z, et al.PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 401. [10] Sonbol MB, Riaz IB, Naqvi SAA, et al.Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis[J]. JAMA Oncol, 2020, 6(12): e204930. [11] Seo SI, Kim HS, Kim WJ, et al.Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(13): 3928-3935. [12] 吴孟超, 陈汉, 沈锋. 原发性肝癌的外科治疗5524例报告[J]. 中华外科杂志, 2001, 39(6): 417-419. [13] 王黎明, 吴凡, 吴健雄, 等. 控制手术相关危险因素后肝癌术后复发危险因素分析[J]. 中华肿瘤杂志, 2014, 36(8): 629-634. [14] Tabrizian P, Jibara G, Shrager B, et al.Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis[J]. Ann Surg, 2015, 261(5): 947-955. [15] Chan AWH, Zhong J, Berhane S, et al.Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection[J]. J Hepatol, 2018, 69(6): 1284-1293. [16] 张杰, 段伯焕, 朱功兵. 肝细胞癌患者外科手术根治术后生存分析[J].实用肝脏病杂志, 2017, 20(1): 93-96. [17] Lin DX, Zhang QY, Li X, et al.An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus[J]. J Cancer Res Clin Oncol, 2011, 137(1): 139-149. [18] Cheng Z, Yang P, Qu S, et al.Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection[J]. HPB (Oxford), 2015, 17(5): 422-427. [19] D′Amico G, Morabito A, D′Amico M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3): 563-576. [20] Ryu T, Takami Y, Wada Y, et al.A Clinical Scoring System for Predicion of Microvascular Invasion in Patique of Hepatocellular Carcinoma within the Milan Criteria[J]. J Gastrointest Surg, 2019, 23(4): 779-787. [21] Nitta H, Allard MA, Sebagh M, et al.Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2019, 26(8): 2568-2576. [22] Feng H, Li B, Li Z, et al.PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 401. [23] Pawlik TM, Delman KA, Vauthey JN, et al.Tumor size predicts vascular invasion and histologic grade: Implications forselection of surgical treatment for hepatocellular carcinoma[J]. Liver Transpl, 2005, 11: 1086-1092. [24] Onaca N, Davis GL, Jennings LW, et al.Improved results of transplantation forhepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation[J]. Liver Transpl, 2009, 15: 574-580. [25] Okusaka T, Okada S, Ueno H, et al.Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features[J]. Cancer, 2002, 95(9): 1931-1937. [26] Lim C, Mise Y, Sakamoto Y, et al.Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J].World J Surg, 2014, 38(11): 2910-2918. [27] Guerrini GP, Pinelli D, Di Benedetto F, et al.Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation[J]. Surg Oncol, 2016, 25(4): 419-428. |